down arrow

Zevra Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US4884452065
USD
8.66
0.49 (6.0%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

8.478.80

52 Week

6.1913.16
Valuation
Technical
Day's Volume

CASH

825.27 k

Shareholding (Jun 2025)

FII

3.72%

Held by 31 FIIs

DII

76.92%

Held by 23 DIIs

Promoter

0.02%

What does Zevra Therapeutics, Inc. do?

22-Jun-2025

Zevra Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $20 million and a net loss of $3 million as of March 2025. Key financial metrics include a market cap of $481.73 million and a return on equity of -232.30%.

Overview: <BR>Zevra Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 20 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 481.73 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.05 <BR>Return on Equity: -232.30% <BR>Price to Book: 11.74<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Read More

Is Zevra Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of October 3, 2023, Zevra Therapeutics, Inc. is considered attractive due to its undervalued financial metrics, including a P/E ratio of 15.2 and a P/B ratio of 1.8, which are lower than peers like Acadia Pharmaceuticals and Zymeworks, and its recent stock performance has outpaced the Sensex.

As of 3 October 2023, Zevra Therapeutics, Inc. moved from fair to attractive. The company appears to be undervalued based on its current financial metrics. Key ratios include a Price-to-Earnings (P/E) ratio of 15.2, a Price-to-Book (P/B) ratio of 1.8, and a Debt-to-Equity (D/E) ratio of 0.5, which indicate a solid financial position relative to its earnings and asset base.<BR><BR>In comparison to peers, such as Acadia Pharmaceuticals with a P/E of 20.1 and Zymeworks at a P/B of 3.0, Zevra's ratios suggest it is trading at a discount. This valuation is further supported by the company's recent stock performance, which has outpaced the Sensex, reinforcing the attractiveness of its current price point.

Read More

Is Zevra Therapeutics, Inc. technically bullish or bearish?

28-Oct-2025

As of October 24, 2025, Zevra Therapeutics, Inc. shows a mildly bullish trend with positive momentum from MACD and moving averages, but caution is advised due to mixed signals from KST and Dow Theory.

As of 24 October 2025, the technical trend for Zevra Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD remains bullish, and the monthly MACD is also bullish, indicating positive momentum. The daily moving averages are bullish, supporting the mildly bullish stance. However, the KST shows a mildly bearish signal on the weekly timeframe, and the Dow Theory indicates a mildly bearish trend on the monthly timeframe. The Bollinger Bands are mildly bullish weekly and bullish monthly, suggesting some upward potential. Overall, the indicators present a mildly bullish outlook, but with caution due to mixed signals from KST and Dow Theory. Multi-period return data is not available for comparison with the S&P 500.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a growth in Net Sales of 26.86%, the company declared Outstanding results in Jun 25

  • ROCE(HY) Highest at 3.53%
  • RAW MATERIAL COST(Y) Fallen by -187.81% (YoY)
  • CASH AND EQV(HY) Highest at USD 265.24 MM
2

With ROE of -232.30%, it has a risky valuation with a 12.34 Price to Book Value

3

High Institutional Holdings at 76.89%

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 468 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.21

stock-summary
Return on Equity

53.63%

stock-summary
Price to Book

3.99

Revenue and Profits:
Net Sales:
26 Million
(Quarterly Results - Jun 2025)
Net Profit:
75 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.91%
0%
-2.91%
6 Months
-2.37%
0%
-2.37%
1 Year
-7.87%
0%
-7.87%
2 Years
74.6%
0%
74.6%
3 Years
79.3%
0%
79.3%
4 Years
12.18%
0%
12.18%
5 Years
-37.79%
0%
-37.79%

Zevra Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Zevra Therapeutics Experiences Revision in Stock Evaluation Amid Strong Market Performance

Zevra Therapeutics Experiences Revision in Stock Evaluation Amid Strong Market Performance

Zevra Therapeutics, Inc. has recently revised its evaluation amid changing market conditions. The company’s stock price has risen, and it has achieved a significant annual return, outperforming the S&P 500. Technical indicators show a mix of bullish and mildly bearish trends, reflecting its competitive position in the market.

Read More

Is Zevra Therapeutics, Inc. technically bullish or bearish?

As of 24 October 2025, the technical trend for Zevra Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD remains bullish, and the monthly MACD is also bullish, indicating positive momentum. The daily moving averages are bullish, supporting the mildly bullish stance. However, the KST shows a mildly bearish signal on the weekly timeframe, and the Dow Theory indicates a mildly bearish trend on the monthly timeframe. The Bollinger Bands are mildly bullish weekly and bullish monthly, suggesting some upward potential. Overall, the indicators present a mildly bullish outlook, but with caution due to mixed signals from KST and Dow Theory. Multi-period return data is not available for comparison with the S&P 500....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
23.21%
EBIT Growth (5y)
-288.18%
EBIT to Interest (avg)
-14.46
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.05
Sales to Capital Employed (avg)
0.25
Tax Ratio
22.06%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
76.89%
ROCE (avg)
10.83%
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
12.34
EV to EBIT
-7.02
EV to EBITDA
-7.71
EV to Capital Employed
12.91
EV to Sales
12.43
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-183.97%
ROE (Latest)
-232.30%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 31 Schemes (19.34%)

Foreign Institutions

Held by 31 Foreign Institutions (3.72%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 26.96% vs 70.00% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 2,509.68% vs 91.32% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "25.90",
          "val2": "20.40",
          "chgp": "26.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.70",
          "val2": "-3.70",
          "chgp": "-189.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.00",
          "val2": "2.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-59.50",
          "val2": "4.90",
          "chgp": "-1,314.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "74.70",
          "val2": "-3.10",
          "chgp": "2,509.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-476.40%",
          "val2": "-262.80%",
          "chgp": "-21.36%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -14.18% vs 169.61% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -129.35% vs -71.64% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "23.60",
          "val2": "27.50",
          "chgp": "-14.18%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-80.60",
          "val2": "-48.60",
          "chgp": "-65.84%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "7.40",
          "val2": "1.50",
          "chgp": "393.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "2.00",
          "val2": "0.50",
          "chgp": "300.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-105.50",
          "val2": "-46.00",
          "chgp": "-129.35%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-3,684.70%",
          "val2": "-1,806.30%",
          "chgp": "-187.84%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
25.90
20.40
26.96%
Operating Profit (PBDIT) excl Other Income
-10.70
-3.70
-189.19%
Interest
2.00
2.00
Exceptional Items
-59.50
4.90
-1,314.29%
Consolidate Net Profit
74.70
-3.10
2,509.68%
Operating Profit Margin (Excl OI)
-476.40%
-262.80%
-21.36%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 26.96% vs 70.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 2,509.68% vs 91.32% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
23.60
27.50
-14.18%
Operating Profit (PBDIT) excl Other Income
-80.60
-48.60
-65.84%
Interest
7.40
1.50
393.33%
Exceptional Items
2.00
0.50
300.00%
Consolidate Net Profit
-105.50
-46.00
-129.35%
Operating Profit Margin (Excl OI)
-3,684.70%
-1,806.30%
-187.84%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -14.18% vs 169.61% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -129.35% vs -71.64% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Zevra Therapeutics, Inc. stock-summary
stock-summary
Zevra Therapeutics, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."